| Spruce Bio Raises $88M for Clinical Tests of Rare Endocrine Disease Drug | Frank Vinluan | 02/20/20 | San Francisco |
| Bio Roundup: Goodbye Belviq, LogicBio on Hold, Revolution’s IPO & More | Frank Vinluan | 02/14/20 | National |
| Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks | Frank Vinluan | 02/13/20 | National |
| Millendo Picks Poxel’s Arbet-Engels for Chief Medical Officer Post | Frank Vinluan | 02/12/20 | Detroit Ann Arbor |
| Two Big Pharma Alliances End in Nixed Deals. Here’s What Happened. | Frank Vinluan | 02/11/20 | National |
| Eli Lilly, Roche Drugs Fail to Move Needle in Genetically Driven Alzheimer’s | Frank Vinluan | 02/10/20 | National |
| Bio Roundup: POTUS on Prices, a16z’s Fund, Aimmune’s Approval & More | Sarah de Crescenzo | 02/07/20 | National |
| Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy | Frank Vinluan | 01/31/20 | San Francisco |
| Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More | Frank Vinluan | 01/31/20 | National |
| BIO Report: More Work Needed to Improve Diversity at Biotech Firms | Sarah de Crescenzo | 01/30/20 | National |
| BioIntelliSense Debuts “Sticker” Sensor to Capture Patient Data Remotely | Sarah de Crescenzo | 01/28/20 | Boulder/Denver |
| Advanced Therapies Are Reshaping Biopharma R&D: KPMG Report | Gareth Macdonald | 01/28/20 | National |
| Life Sciences IPOs Target Collective Raise of More Than $600M This Week | Sarah de Crescenzo | 01/27/20 | National |
| Bio Roundup: Coronavirus Concerns, Sarepta’s CRL, Eye Drug OK’d & More | Sarah de Crescenzo | 01/24/20 | National |
| Bio Roundup: EQRx’s Ambitions, Nektar No Vote, New Frazier Fund & More | Frank Vinluan | 01/17/20 | National |
| FDA Panel Votes Down Nektar Opioid Painkiller, Asks for More Data | Frank Vinluan | 01/14/20 | National |
| Biotech Roundup: Drug Pricing Promises, Bone Disease Data, IPO Plans & More | Sarah de Crescenzo | 01/10/20 | National |
| Bio Roundup: FDA Approvals, Intrexon’s Shift, Melinta Bankruptcy & More | Frank Vinluan | 01/03/20 | National |
| Bio Roundup: Amarin’s Approval, FTC v. Illumina, a $120M Deal & More | Sarah de Crescenzo | 12/20/19 | National |
| Bio Roundup: Sarepta’s Approval, Merck M&A, Drug Price Bill & More | Frank Vinluan | 12/13/19 | National |
| Iterum’s Antibiotic for Super Bugs Falls Short in Phase 3, Shares Sink | Frank Vinluan | 12/11/19 | National |
| Bio Roundup: Biogen at CTAD, Sage’s Stumble, Astellas’s $3B Offer & More | Sarah de Crescenzo | 12/06/19 | National |
| Digital Health Survivors & Innovative Incumbents Must Team Up for True Disruption | Bryony Winn | 12/04/19 | Raleigh Durham |
| Partner or Die: How to Succeed Even After the Digital Health Hype Quiets Down | Rob Coppedge | 12/03/19 | Seattle |
| Bio Roundup: So Long Celgene, RNAi’s Arrival, Pharma in 2020 & More | Frank Vinluan | 11/22/19 | National |
| Biopharma Execs Remain Optimistic Despite Political Headwinds | Mike Ward | 11/20/19 | National |
| Biotech Roundup: Gottlieb v. Juul, Solid Slumps, Avidity Gets $100M & More | Sarah de Crescenzo | 11/15/19 | National |
| Daré to Add Microchip-Based Birth Control to Women’s Health Portfolio | Sarah de Crescenzo | 11/15/19 | San Diego |
| Neuroscience Is Taking the Spotlight at Xconomy’s Bay Area Xchange | Frank Vinluan | 11/11/19 | San Francisco |
| Bio Roundup: Feds Sue Gilead, Biogen Eyes China, CRISPR’d Kidneys & More | Frank Vinluan | 11/08/19 | National |
